Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the sale of its portfolio company Corvidia Therapeutics to Novo Nordisk, for $2.1 billion, including an upfront payment of $725 million. Corvidia, an AstraZeneca spin-off, is a clinical-stage company focused on the research, development and commercialization of transformative therapies for cardio-renal diseases. Sofinnova Partners was Corvidia’s sole seed financial investor in 2015 and it has remained the largest shareholder throughout the company’s evolution.
Sofinnova Partners helped recruit Corvidia’s top management team members, including Sylvie Grégoire, a seasoned pharma executive and entrepreneur, in 2016, to chair the Board, and Marc de Garidel as Chief Executive Officer in 2018. Before joining Corvidia, Mr. de Garidel was the Chairman and CEO of Ipsen, a publicly-listed French pharmaceutical company.
Graziano Seghezzi, Managing Partner at Sofinnova Partners, commented, “This acquisition is the culmination of a quintessential Sofinnova Partners investment, from seed to exit. We are especially proud of the high-caliber team we helped establish, which includes veteran executives like Marc de Garidel, who has been instrumental in this deal.”
Mr. de Garidel, CEO of Corvidia, said, “Sofinnova Partners has played a central role in building this company from the very beginning, leveraging its extensive international network to bring in key hires and providing strategic guidance to advance our scientific work around precision therapies for cardiovascular diseases.”
Sofinnova Partners co-founded Corvidia alongside Michael Davidson, M.D., a serial entrepreneur and a recognized authority in the field of cardiology. Dr. Davidson was co-founder and Chief Medical Officer of Omthera Pharmaceuticals, for which Sofinnova Partners was also the lead investor, and which was acquired by AstraZeneca for $443 million in 2013.
Mr. Seghezzi added, “This milestone demonstrates the strength of our cornerstone strategy of backing extraordinary entrepreneurs with whom we have long-standing relationships. Moreover, it exemplifies the resilience of our business of developing game-changing therapies that will impact patients’ lives, while consistently generating outsized venture returns for investors, despite the challenges of the current global crisis.”
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com
About Corvidia Therapeutics
Based in Boston, MA, Corvidia is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company’s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia’s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. For more information, please visit: www.corvidiatx.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005512/en/
Contact information
Media Contacts:
Bommy Lee
Head of Communications, Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
Italy
Havas PR Milan
Marco Fusco
Marco.fusco@havaspr.com
+39 (0) 3456538145
Antonio Buozzi
antonio.buozzi@havaspr.com
+39 (0) 3200624418
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneyco.com
+1 212 223 0561
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Heidrick & Struggles Appoints a New Managing Partner for Their CEO & Board Practice in Europe and Africa2.5.2025 11:27:00 EEST | Press release
Heidrick & Struggles (Nasdaq: HSII), a premier provider of executive search, global leadership advisory and on-demand talent solutions, has appointed Kati Najipoor-Smith as Regional Co-Managing Partner, CEO & Board Practice, for Europe and Africa. Based at the Firm’s office in Frankfurt, Germany, Kati brings decades of global executive search and consulting experience to the Heidrick & Struggles team to support boards and CEOs in navigating complex leadership challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501269229/en/ Kati Najipoor-Smith has been appointed Heidrick & Struggles' Regional Co-Managing Partner, CEO & Board Practice, for Europe and Africa Kati began her executive search career at Egon Zehnder in 1999, where she led Global Automotive and later the Global CEO Practice over several years. She advises chairs and CEOs of publicly traded, family-owned, and private-equity-backed companies across sectors
Valeo Foods Group Acquires Freddi Dolciaria S.p.A, Enhancing its Position in the Italian Bakery Sector2.5.2025 11:00:00 EEST | Press release
Valeo Foods Group, one of Europe’s leading producers of quality sweets, treats and snacks, has successfully acquired the Italian sweet bakery producer Freddi Dolciaria S.p.A (“Freddi”), accelerating growth in South-West European region and enhancing its position in the bakery sector. Freddi is an Italian sweet bakery company founded in 1949 by Luigi Freddi and headquartered in Castiglione delle Stiviere, Italy. Specialising in sponge cakes, Freddi has an established presence in both the Italian retail and international markets, with an annual turnover approaching €20 million and 48 employees. This acquisition strengthens Valeo Foods Group’s position in the packaged wafers, cakes, and biscuits category, complementing the existing Balconi business across Southern Europe and international markets. The integration of Freddi is expected to drive sustainable, profitable growth while enhancing production capacity and operational efficiency. It also reinforces Valeo’s continued expansion in th
Perma-Pipe International Holdings, Inc. Announces Fourth Quarter and Fiscal 2024 Financial Results1.5.2025 23:24:00 EEST | Press release
Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the fourth quarter and 2024 fiscal year ended January 31, 2025. “Sales for the fourth quarter and full year 2024 show moderate growth and were $45.0 million and $158.4 million, resulting in increases of $4.8 million and $7.7 million, compared to the prior year. Income before taxes was $5.3 million and $18.5 million in the fourth quarter and for the full year 2024, which increased by $2.1 million and $8.6 million, compared to the prior year. This significant increase was a result of our focus on higher margin products and services that contributed to improved margin performance. Net income after taxes and minority interest was $1.5 million and $9.0 million in the fourth quarter and for the full year 2024. Although 2024 net income was a decrease of $1.5 million, compared to $10.5 million last year, the reduction was due to a one-time non-cash tax benefit of $5.9 million in the prior year after be
IFF Declares Dividend for Second Quarter 20251.5.2025 23:15:00 EEST | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 11, 2025 to shareholders of record as of June 20, 2025. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20250501776988/en/
Rimini Street Announces Fiscal First Quarter 2025 Financial and Operating Results1.5.2025 23:01:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal first quarter ended March 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501664008/en/ Select First Quarter 2025 Financial Results Revenue was $104.2 million for the 2025 first quarter, a decrease of 2.4% compared to $106.7 million for the same period last year. U.S. revenue was $50.1 million for the 2025 first quarter, a decrease of 6.9% compared to $53.8 million for the same period last year. International revenue was $54.1 million for the 2025 first quarter, an increase of 2.2% compared to $52.9 million for the same period last year. Subscription revenue was $99.0 million, which accounted for 95.0% of total revenue for the 2025 first quarter, compared to subscription rev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom